8-K: Salarius Pharmaceuticals Reports Preliminary Cash Position and Completes Equity Sale

Salarius Pharmaceuticals disclosed a preliminary cash balance of $2.4 million as of December 31, 2024, and completed the sale of 141,000 shares of common stock for $493,500.

Summary

• Salarius Pharmaceuticals estimates its cash and cash equivalents to be $2.4 million as of December 31, 2024.
• These cash figures are preliminary and unaudited, and are subject to change after the completion of the company's audited financial statements for the year ended December 31, 2024.
• The company sold 141,000 shares of common stock to C/M Capital Master Fund, LP for $3.50 per share, totaling $493,500.
• An additional 1,410 shares were issued to the investor as commitment shares.
• The sale of these shares was exempt from registration under the Securities Act of 1933.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. The company has raised some capital, but the cash position is still low and subject to change after the audit.

Positives

• The company successfully raised $493,500 through an equity sale.
• The company has a preliminary cash balance of $2.4 million.

Negatives

• The cash balance of $2.4 million is preliminary and unaudited.
• The company's financial position is subject to change upon completion of the audited financial statements.

Risks

• The preliminary cash balance is subject to change after the audit.
• The company's financial position and results of operations are not fully understood without additional information and disclosures.

Future Outlook

The company's financial position and results of operations as of December 31, 2024, are subject to change upon completion of the audited financial statements.

Management Comments

• The company's Executive Vice President & Chief Financial Officer, Mark J. Rosenblum, signed the report on behalf of the company.

Industry Context

This announcement reflects a common practice for small pharmaceutical companies to raise capital through equity sales to fund operations and research.

Comparison to Industry Standards

• Many small-cap biotech companies like Salarius rely on private placements to raise capital, similar to companies such as Aeterna Zentaris and Oncolytics Biotech.
• The cash position of $2.4 million is relatively low for a company in the clinical stage of drug development, which is similar to other companies at this stage such as Veru Inc. and Cassava Sciences.
• The share price of $3.50 per share is typical for private placements in the biotech sector, which is similar to recent placements by companies such as BioVie Inc. and Cyclacel Pharmaceuticals.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company's ability to fund operations and research is improved by the capital raise.

Next Steps

• The company will complete its audited financial statements for the year ended December 31, 2024.
• The company will likely continue to seek funding for its operations and research.

Key Dates

Keywords

equity financing, cash position, share issuance, preliminary results, financial condition, Salarius Pharmaceuticals